Herzelia-Pituah, Israel, May 24, 2006 – MD Biosciences, a global biotechnology company focused in inflammations research, announced today that it has expanded its Israel facility with the launch of its Neurology Discovery Services. The expanded laboratory in Israel provides the necessary capacity to accommodate the company’s growing service portfolio, adding additional models for Multiple Sclerosis and launching new models for Alzheimer’s disease, Nociception, Neuropathic and Inflammatory Pain. The rising number of pharmaceutical and biotechnology companies working within drug discovery and the strong emphasis on outsourcing increases MD Biosciences market potential.
